Mexico-based pharmaceutical company Genomma Lab Internacional, S.A.B. de C.V. (BMV:LAB B) on Wednesday reported its financial results for the second quarter of 2025.

Genomma's second quarter sales grew +0.5%, or +5.5% excluding Argentina, reflecting a significant depreciation in the Argentine peso and a weak beverage season in Mexico. However, the company said that its profitability remained solid, with +4.4% EBITDA growth, margin expanding +89 bps to 23.8%, and a proforma net income increase of +16.6% (excluding non-cash FX related effects). These profitability levels and a 7-day improvement in cash conversion cycle drove a +64.6% free-cash-flow increase for the trailing 12 months.

Genomma added that, as it navigates macroeconomic headwinds in 2025, the company remains focused on executing its growth projects while maintaining an average EBITDA margin of 24% through its ongoing productivity programme.